ATE507242T1 - Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon - Google Patents

Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon

Info

Publication number
ATE507242T1
ATE507242T1 AT06755161T AT06755161T ATE507242T1 AT E507242 T1 ATE507242 T1 AT E507242T1 AT 06755161 T AT06755161 T AT 06755161T AT 06755161 T AT06755161 T AT 06755161T AT E507242 T1 ATE507242 T1 AT E507242T1
Authority
AT
Austria
Prior art keywords
binding molecules
host cell
applications
specific binding
human binding
Prior art date
Application number
AT06755161T
Other languages
English (en)
Inventor
Mark Throsby
Kruif Cornelis De
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of ATE507242T1 publication Critical patent/ATE507242T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT06755161T 2005-05-12 2006-05-11 Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon ATE507242T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EPPCT/EP2005/052160 2005-05-12
EPPCT/EP2005/052648 2005-06-08
EPPCT/EP2005/052946 2005-06-23
EPPCT/EP2005/054002 2005-08-15
PCT/EP2006/062250 WO2006120230A2 (en) 2005-05-12 2006-05-11 Host cell specific binding molecules capable of neutralizing viruses and uses thereof

Publications (1)

Publication Number Publication Date
ATE507242T1 true ATE507242T1 (de) 2011-05-15

Family

ID=37396920

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06755161T ATE507242T1 (de) 2005-05-12 2006-05-11 Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon

Country Status (7)

Country Link
US (2) US8052974B2 (de)
EP (1) EP1879921B1 (de)
AT (1) ATE507242T1 (de)
AU (1) AU2006245734C1 (de)
CA (1) CA2608058C (de)
IL (1) IL187321A (de)
WO (1) WO2006120230A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
ES2408582T3 (es) 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
DK1749029T3 (da) 2004-05-27 2011-06-06 Crucell Holland Bv Bindemolekyler, der kan neutralisere rabiesvirus, og anvendelser deraf
AU2006245734C1 (en) 2005-05-12 2012-05-24 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
MY170607A (en) 2006-09-07 2019-08-20 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
JP2013538042A (ja) * 2010-06-16 2013-10-10 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション エンドプラスミンに対する抗体およびその使用
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
NZ772318A (en) 2012-04-20 2023-06-30 Merus Nv Methods and means for the production of ig-like molecules
KR101815265B1 (ko) * 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
CN113817053A (zh) 2014-02-11 2021-12-21 威特拉公司 用于登革病毒的抗体分子及其应用
AU2016222599B2 (en) 2015-02-25 2020-03-19 The Board Of Regents Of The University Of Texas System Antibody-mediated neutralization of Marburg virus
JP6811723B2 (ja) 2015-04-17 2021-01-13 アイジーエム バイオサイエンシズ インコーポレイテッド 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法
EP3297673A4 (de) * 2015-05-22 2019-05-08 Memorial Sloan-Kettering Cancer Center Für ein prame-peptid spezifische t-zell-rezeptor-ähnliche antikörper
AU2017238651B2 (en) 2016-03-25 2024-06-13 Visterra, Inc. Formulation of antibody molecules to dengue virus
WO2019036856A1 (en) * 2017-08-21 2019-02-28 Adagene Inc. DYNAMIC BANKS OF LIGHT CHAIN OF HUMAN ANTIBODY
CN111279024A (zh) 2017-08-21 2020-06-12 天演药业公司 动态人重链抗体文库

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4529700A (en) 1982-08-20 1985-07-16 University Of Miami Hybridoma cells secreting a monoclonal antibody specific for 5-bromo and 5-iodoeoxyuridine and reagents for measuring cellular proliferation
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) * 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
US5494671A (en) * 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
ES2153223T3 (es) 1991-09-19 2001-02-16 Us Health Flavivirus quimericos y/o flavivirus de crecimiento restringido.
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
HU219503B (hu) 1994-07-08 2001-04-28 Baxter Aktiengesellschaft Javított vakcina TBE-vírusfertőzés elleni immunizálásra, valamint eljárás az előállítására
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US6455509B1 (en) * 1996-06-04 2002-09-24 The United States Of America As Represented By The Secretary Of The Navy Dengue nucleic acid vaccines that induce neutralizing antibodies
EP0947581A4 (de) 1996-08-08 2004-07-28 Mitsubishi Pharma Corp Kulturmedium und seine verwendung.
AU4474497A (en) 1996-10-08 1998-05-05 U-Bisys B.V. Methods and means for selecting peptides and proteins having specific affinity for a target
ATE297757T1 (de) 1997-02-28 2005-07-15 Acambis Inc Chimäre impfstoffe gegen flaviviren
US6258788B1 (en) * 1997-11-20 2001-07-10 The United States Of America As Represented By The Secretary Of The Army DNA vaccines against tick-borne flaviviruses
CA2331368C (en) 1998-06-04 2009-02-10 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nucleic acid vaccines for prevention of flavivirus infection
CN1342156A (zh) 1998-08-25 2002-03-27 耶鲁大学 用赛菊宁黄质及其类似物抑制和治疗乙型肝炎病毒和黄病毒
US6416763B1 (en) 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
EP1108036B1 (de) 1998-09-02 2010-06-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Dengue viren, die in mosquitos nicht replizieren, zur verwendung als impfstoff
US6685948B1 (en) * 1998-09-02 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Replication-defective dengue viruses that are replication-defective in mosquitoes for use as vaccines
ES2237420T5 (es) 1999-04-15 2010-03-03 Crucell Holland B.V. Produccion de proteina recombinante en una celula humana.
US6432411B1 (en) * 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
EP1103610A1 (de) 1999-11-26 2001-05-30 Introgene B.V. Impfstoffherstellung von immortalisierten Säugetierzellinien
WO2001039802A1 (en) 1999-12-01 2001-06-07 Oravax, Inc. Chimeric flavivirus vaccines
AU3844101A (en) 2000-02-16 2001-08-27 Us Health Avirulent, immunogenic flavivirus chimeras
JP2003523978A (ja) 2000-02-18 2003-08-12 シャイアー・バイオケム・インコーポレイテッド ヌクレオシドアナログを用いるｆｌａｖｉｖｉｒｕｓ感染の処置もしくは予防するための方法
CA2411374C (en) * 2000-06-29 2012-10-30 Abbott Laboratories Dual specificity antibodies and methods of making and using
US6946125B2 (en) * 2000-08-23 2005-09-20 The New York Hospital Medical Center Of Queens Methods of treating West Nile virus infection
WO2002072036A2 (en) * 2001-03-12 2002-09-19 Yale University Compositions and methods comprising west nile virus polypeptides
EP1402025B1 (de) 2001-06-15 2006-02-01 Crucell Holland B.V. Chimäre phagen
PL212212B1 (pl) 2001-07-27 2012-08-31 Wyeth Corp Kompozycja szczepionki przeciwko zakażeniu wirusem Zachodniego Nilu, kompozycja końskiej szczepionki, szczepionka wirusa Zachodniego Nilu oraz zastosowania
US20040258699A1 (en) 2002-02-11 2004-12-23 Bowdish Katherine S. Immunotherapeutics for biodefense
WO2003076568A2 (en) 2002-02-11 2003-09-18 Alexion Pharmaceuticals, Inc. Immunotherapeutics for biodefense
PL214284B1 (pl) 2002-07-09 2013-07-31 Baxter Healthcare Sa Sposób wytwarzania wirusa oraz sposób wytwarzania immunogennej kompozycji zawierajacej wirusa albo antygen wirusa
US6875433B2 (en) * 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
EP1601947A2 (de) 2002-10-31 2005-12-07 Health Research, Incorporated Diagnostischer test für west-nil-virus
CA2501220C (en) 2002-11-08 2012-01-17 Crucell Holland B.V. Vaccines against west nile virus
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP1647596A4 (de) 2003-07-18 2008-02-13 Mochida Pharm Co Ltd Monoklonaler antikörper gegen glycoprotein vi der blutplättchenmembran
KR101206206B1 (ko) 2003-07-22 2012-11-29 크루셀 홀란드 비.브이. 사스-코로나바이러스에 대한 결합분자 및 그것의 용도
WO2005063819A2 (en) 2003-12-23 2005-07-14 Crucell Holland B.V. Human binding molecule against cd1a
US7074555B2 (en) * 2004-04-28 2006-07-11 Idexx Laboratories, Inc. Detection of West Nile Virus
WO2005111623A1 (en) 2004-05-17 2005-11-24 Crucell Holland B.V. Methods for diagnosis of acute myeloid leukemia
DK1749029T3 (da) 2004-05-27 2011-06-06 Crucell Holland Bv Bindemolekyler, der kan neutralisere rabiesvirus, og anvendelser deraf
US20090130123A1 (en) 2004-06-15 2009-05-21 Erol Fikrig Antibodies to west nile virus polypeptides
US7527973B2 (en) 2004-06-21 2009-05-05 Washington University Antibodies against West Nile Virus and therapeutic and prophylactic uses thereof
MX2007002883A (es) 2004-09-13 2007-06-15 Macrogenics Inc Anticuerpos humanizados contra el virus de nilo occidental y usos terapeuticos y profilacticos del mismo.
JP4852046B2 (ja) 2004-10-12 2012-01-11 クルセル ホランド ベー ヴェー 癌の治療及び検出に用いる結合分子
WO2007011392A2 (en) 2004-10-14 2007-01-25 Washington University Crystal structure of domain 111 of west nile virus envelope protein-fab fragment of neutralizing antibody complex
US8106170B2 (en) 2004-11-11 2012-01-31 Crucell Holland B.V. Compositions against SARS-coronavirus and uses thereof
WO2006056006A1 (en) 2004-11-23 2006-06-01 The University Of Queensland Equine west nile virus immunotherapy
AU2005318171B2 (en) 2004-12-20 2011-09-29 Crucell Holland B.V. Binding molecules capable of neutralizing West Nile virus and uses thereof
AU2006245734C1 (en) 2005-05-12 2012-05-24 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
US20090130652A1 (en) 2005-06-23 2009-05-21 Crucell Holland B.V. Optimization of West Nile Virus Antibodies
WO2007031550A2 (en) 2005-09-15 2007-03-22 Crucell Holland B.V. Method for preparing immunoglobulin libraries
EA031202B1 (ru) 2006-06-06 2018-11-30 Янссен Вэксинс Энд Превеншн Б.В. Антитело человека, обладающее фагоцитарной активностью против стафилококков, и его применение
CA2654502C (en) 2006-06-06 2015-07-14 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and uses thereof
MY170607A (en) 2006-09-07 2019-08-20 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof

Also Published As

Publication number Publication date
AU2006245734A1 (en) 2006-11-16
US20100303801A1 (en) 2010-12-02
US8052974B2 (en) 2011-11-08
IL187321A (en) 2013-06-27
US20120076794A1 (en) 2012-03-29
WO2006120230A3 (en) 2007-06-21
AU2006245734B2 (en) 2011-12-01
IL187321A0 (en) 2008-04-13
AU2006245734C1 (en) 2012-05-24
US8911738B2 (en) 2014-12-16
WO2006120230A2 (en) 2006-11-16
CA2608058C (en) 2013-09-10
EP1879921A2 (de) 2008-01-23
CA2608058A1 (en) 2006-11-16
EP1879921B1 (de) 2011-04-27

Similar Documents

Publication Publication Date Title
ATE507242T1 (de) Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon
CA2865594C (en) Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
DK1749029T3 (da) Bindemolekyler, der kan neutralisere rabiesvirus, og anvendelser deraf
BRPI0510475A (pt) adenovìrus quimérico para o uso no tratamento de cáncer
EA200870594A1 (ru) Связывающие человеческие молекулы с киллерной активностью в отношении энтерококков и их применение
BR112013010857A2 (pt) imonoglubulinas de duplo domínio variável e usos das mesmas
EA201590910A1 (ru) Белки на основе структурного домена фибронектина, связывающие pcsk9
WO2006067122A3 (en) Binding molecules capable of neutralizing west nile virus and uses thereof
ATE460473T1 (de) Immortalisierte entezelllinien zur viruserzeugung
WO2007053189A3 (en) Compositions and methods for altering immune function
EA201201650A1 (ru) Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
WO2014066744A3 (en) Anti-complement c1s antibodies and uses thereof
DE602007008360D1 (de) Aviäre telomerase reverse transkriptase
WO2008108830A8 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
BRPI0919236A8 (pt) Terapêutica e vacinas de combinação de gas
EA201200182A1 (ru) Связывающие человеческие молекулы с киллерной активностью в отношении энтерококков и их применение
MY165458A (en) Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
UA110918C2 (uk) Інгібітори протеїнфосфатази-1 та їх застосування
ATE431555T1 (de) Verfahren und mittel zur bestimmung der replikationsgeschwindigkeit einer viruspopulation
EA202091305A2 (ru) Белки на основе структурного домена фибронектина, связывающие pcsk9
DE602006021562D1 (de) Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties